MetaCap

Aligos Therapeutics (ALGS) vs Jasper Therapeutics (JSPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Jasper Therapeutics (JSPR) has outperformed Aligos Therapeutics (ALGS) over the past year, gaining 411.2% versus a loss of 86.8%. Over five years, JSPR leads with a -89.4% price change compared with -99.7% for ALGS. Jasper Therapeutics is the larger company by market cap ($9.6 million vs $7.6 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALGS-86.75%JSPR+411.18%
+941%+403%-136%
Nov 21, 20251 yearNov 20, 2026
ALGS-99.69%JSPR-89.11%
+30%-38%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALGS versus JSPR key metrics
MetricALGSJSPR
Share price$1.22$8.69
Market cap$7.62M$9.64M
1-day change-2.40%-18.25%
YTD return-86.91%+374.86%
1-year return-86.75%+411.18%
5-year return-99.70%-89.44%
EPS (TTM)$-6.46$-7.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.19M—
Revenue growth (YoY)-39.46%—
Net income (latest FY)$-24.19M$-75.80M
Operating margin-4024.93%—
Net margin-1106.72%—
52-week high$13.69$72.60
52-week low$1.18$8.47
Distance from 52-week high-91.09%-88.03%
Analyst consensusnonenone
Avg. price target upside+4193.44%+130.15%
Average volume57.37K16.89K
Shares outstanding5.45M1.11M
Employees82—
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • JSPR has outperformed ALGS by 497.9 percentage points over the past year.

About Aligos Therapeutics

ALGS stock →

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees

About Jasper Therapeutics

JSPR stock →

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

ALGS vs JSPR FAQ

Which is bigger, Aligos Therapeutics or Jasper Therapeutics?

Jasper Therapeutics (JSPR) is larger, with a market capitalization of $9.64M compared with $7.62M for Aligos Therapeutics (ALGS).

Which stock has performed better over the past year, ALGS or JSPR?

JSPR returned +411.18% over the past 12 months, compared with -86.75% for ALGS (price return, excluding dividends). Past performance does not predict future results.

Are Aligos Therapeutics and Jasper Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons